Acetohydroxamic acid: clinical studies of a urease inhibitor in patients with staghorn renal calculi.
The hydrolysis of urea by the bacterial enzyme urease pathologically increase urinary ammonia, bicarbonate, carconate and alkalinity. These factors contribute to the formation of urinary stones and to the virulence of bacteria. Acetohydroxamic acid, a potent inhibitor of urease, has been administered to 23 patients with staghorn renal calculi and urea-splitting urinary infection. Urinary ammonia and alkalinity has been reduced in every patient. A dose of 1.0 gm. acetohydroxamic acid daily has been well tolerated and effective for 2 to 12 months, even in patients with impaired renal function.
D000641:Ammonia / Q000652:urine; D006801:Humans; D006863:Hydrogen-Ion Concentration; D006868:Hydrolysis; D006877:Hydroxamic Acids / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D007669:Kidney Calculi / Q000188:drug therapy* / Q000652:urine; D007700:Kinetics; D014508:Urea; D014510:Urease / Q000037:antagonists & inhibitors*; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000652:urine
D006877:Hydroxamic Acids; D000641:Ammonia; D014508:Urea; D014510:Urease